Janux Therapeutics price target lowered to $42 from $47 at Scotiabank

Scotiabank lowered the firm’s price target on Janux Therapeutics to $42 from $47 and keeps a Sector Perform rating on the shares. The firm is waiting for updated dose escalation data results and a go-forward dose later this year from the company’s Phase 1 JANX007, for the treatment of metastatic castration resistant prostate cancer, mCRPC, the analyst tells investors. The firm’s rating reflects the competitive landscape of developing mCRPC therapies.